A groundbreaking new study has unveiled a critical and underappreciated health risk faced by millions worldwide: people living with diabetes carry a significantly elevated risk of infections, which in turn contribute substantially to morbidity and mortality. Published in the prestigious journal Diabetes and unveiled at the American Diabetes Association Scientific Sessions in New Orleans, this extensive epidemiological research challenges existing clinical paradigms by quantifying infection risks across the diabetes spectrum—type 1, type 2, and prediabetes—and highlighting the urgent need to incorporate infection management as a foundational pillar in diabetes care guidelines globally.
This comprehensive investigation leveraged anonymized electronic health records from general practitioners (GPs) linked with hospital admission and mortality data, encompassing over 800,000 individuals diagnosed with diabetes or prediabetes across England. These cohorts were rigorously matched by age, sex, and ethnicity against more than one million controls without diabetes, with all participants followed for a five-year period to ascertain infection incidence, hospitalization frequencies, and infection-related deaths. The scale and methodological robustness of this observational cohort study render its findings both compelling and critical for public health policymaking.
The data reveal an alarming stratification of infection risk according to diabetes status. Individuals with type 1 diabetes face an 81% increase in infections diagnosed and managed in primary healthcare, alongside a staggering 337% increased likelihood of hospitalization due to infections when compared to non-diabetic controls. While the infection risk is comparatively lower in people with type 2 diabetes, it remains profoundly elevated—with a 51% rise in primary care-diagnosed infections and a 91% higher rate of hospital admissions for infections. Even those classified as prediabetic exhibit heightened vulnerability, showing 35% and 33% increases in primary care infections and hospital-based infections, respectively. These results unequivocally demonstrate that the interplay between glycemic dysregulation and immune defense compromise is a spectrum rather than a binary condition.
Infections have emerged as a leading cause of mortality in diabetics, trailing only cardiovascular disease and cancer, which traditionally dominate clinical focus. Notably, lower respiratory tract infections—such as pneumonia—constitute the most frequent cause of infection-driven hospitalizations among both type 1 and type 2 diabetics. Sepsis and severe respiratory infections also represent the primary infections leading to fatal outcomes in type 2 diabetic patients. Such findings underscore the pathogen-specific vulnerability in diabetic populations and the necessity for targeted prevention and early intervention strategies.
The pathophysiological underpinnings informing this elevated infection susceptibility are multifactorial. Chronic hyperglycemia induces dysfunction of neutrophil chemotaxis, impaired phagocytosis, and aberrant cytokine production, collectively blunting innate immune responses. Furthermore, microvascular complications reduce tissue perfusion, complicating effective delivery of immune cells to sites of infection. The study further disentangled glycemic control nuances by demonstrating that, in type 1 diabetes, consistently elevated blood glucose levels correlate with heightened infection risk, whereas in type 2 diabetes, fluctuations in glucose levels over time—glycemic variability—are a stronger predictor of severe infections necessitating hospitalization. This nuance implicates not only average glucose concentration but also metabolic instability as key metrics in evaluating infection risk.
These findings hold transformative implications for clinical practice and healthcare policy. Current diabetes management guidelines predominantly emphasize cardiovascular and metabolic complications, with limited acknowledgment of infection risk. The authors advocate for a paradigm shift whereby infection prevention and control become integral components of diabetes care frameworks. This could encompass enhanced patient education on early symptom recognition, prioritization of diabetics in primary care triage systems, and a call for vaccination optimization against respiratory pathogens, including influenza and pneumococcus.
Furthermore, glycemic control parameters must adapt, incorporating measures of variability alongside mean glucose values as standard monitoring markers. Advanced continuous glucose monitoring technologies enable nuanced detection of glycemic excursions, and their routine integration could facilitate individualized infection risk mitigation strategies. This precision medicine approach to diabetes management strives to reduce avoidable hospital admissions and mortality by preempting infections before they escalate.
Professor Julia Critchley, the study’s lead epidemiologist, highlights the magnitude and underrecognition of infection risks in diabetes: “Infections are a major health hazard across the diabetes spectrum and are hiding in plain sight. They are common, serious, and often preventable, yet they are mostly absent from clinical guidelines. The number of people living with diabetes worldwide is rapidly increasing, and it’s a disservice if infection risk remains an afterthought.” Her clarion call urges healthcare authorities to revise guidelines in the UK, Europe, and the United States, prioritizing the earliest possible detection and intervention—a measure poised to save countless lives.
This study also lays a foundation for future research exploring mechanistic links between glycemic metrics and immune dysfunction, and testing the efficacy of targeted interventions such as infection-focused patient education, vaccination compliance enhancement, and metabolic stabilization therapies. It provokes crucial questions about whether more aggressive glycemic variability control could reduce infection incidence and severity, potentially redefining diabetes management outcomes.
Funding for this pivotal research was provided by the National Institute for Health and Care Research (NIHR), marking a significant investment in addressing a previously neglected yet profound diabetes complication. The study exemplifies interdisciplinary collaboration, intersecting epidemiology, immunology, endocrinology, and public health policy to address a complex challenge with global health repercussions.
As the global prevalence of diabetes continues its upward trajectory, with projections estimating a substantial rise over the coming decades, the ramifications of unaddressed infection risks could strain healthcare systems. This study’s call to action for embedding infection prevention and management into diabetes care is timely and urgent, offering a clear path toward holistic, integrated, and life-saving diabetes healthcare delivery.
In conclusion, this landmark research reframes infections not as ancillary issues but as central, life-altering complications within the diabetes continuum. Enhanced awareness, refined clinical guidelines, and tailored patient management strategies focusing on preventing and promptly treating infections offer a hopeful horizon in reducing diabetes-related hospitalizations and death. The diabetes care community now stands at a pivotal juncture—a chance to revolutionize treatment protocols and improve patient outcomes worldwide by acknowledging and addressing this hidden yet formidable health hazard.
Subject of Research: People
Article Title: Increased risk of infections in people living with diabetes
News Publication Date: 6-Jun-2026
Keywords: Health care policy; Type 2 diabetes; Type 1 diabetes; Disease incidence; Health care delivery
